Read + Share

Amedeo Smart

Independent Medical Education


Read + Share

Tarhini AA, Rafique I, Floros T, Tran P, et al. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 2017 May 4. doi: 10.1002/cncr.30717.
PMID: 28472537


Free Medical Abstracts
Privacy Policy
Sponsors
Share
About

© Amedeo 1997-2016